Analysts expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to report sales of $53.35 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Meridian Bioscience’s earnings. The lowest sales estimate is $53.23 million and the highest is $53.47 million. Meridian Bioscience reported sales of $54.13 million during the same quarter last year, which suggests a negative year-over-year growth rate of 1.4%. The business is expected to announce its next earnings results on Thursday, April 26th.
According to Zacks, analysts expect that Meridian Bioscience will report full year sales of $53.35 million for the current year, with estimates ranging from $208.59 million to $210.52 million. For the next fiscal year, analysts forecast that the firm will post sales of $218.58 million per share, with estimates ranging from $216.75 million to $220.10 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Meridian Bioscience.
Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings results on Thursday, January 25th. The company reported $0.15 EPS for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.01. The business had revenue of $52.30 million for the quarter, compared to analyst estimates of $49.00 million. Meridian Bioscience had a return on equity of 17.00% and a net margin of 10.46%. Meridian Bioscience’s quarterly revenue was up 11.8% compared to the same quarter last year. During the same period last year, the company posted $0.15 earnings per share.
Institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC increased its position in Meridian Bioscience by 3.9% in the second quarter. Teachers Advisors LLC now owns 71,829 shares of the company’s stock worth $1,131,000 after buying an additional 2,692 shares during the last quarter. TIAA CREF Investment Management LLC increased its position in Meridian Bioscience by 1.1% in the second quarter. TIAA CREF Investment Management LLC now owns 115,208 shares of the company’s stock worth $1,815,000 after buying an additional 1,294 shares during the last quarter. Ameriprise Financial Inc. increased its position in Meridian Bioscience by 11.9% in the second quarter. Ameriprise Financial Inc. now owns 267,557 shares of the company’s stock worth $4,215,000 after buying an additional 28,488 shares during the last quarter. Thrivent Financial For Lutherans increased its position in Meridian Bioscience by 8.0% in the second quarter. Thrivent Financial For Lutherans now owns 25,520 shares of the company’s stock worth $402,000 after buying an additional 1,880 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its position in Meridian Bioscience by 0.7% in the second quarter. UBS Asset Management Americas Inc. now owns 13,091 shares of the company’s stock worth $206,000 after buying an additional 92 shares during the last quarter. Institutional investors and hedge funds own 85.37% of the company’s stock.
Shares of Meridian Bioscience (NASDAQ:VIVO) opened at $14.10 on Wednesday. The company has a market capitalization of $605.00, a price-to-earnings ratio of 21.03 and a beta of 0.98. Meridian Bioscience has a fifty-two week low of $12.45 and a fifty-two week high of $16.45. The company has a current ratio of 5.82, a quick ratio of 3.96 and a debt-to-equity ratio of 0.28.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Monday, February 5th will be issued a dividend of $0.125 per share. The ex-dividend date of this dividend is Friday, February 2nd. This represents a $0.50 dividend on an annualized basis and a yield of 3.55%. Meridian Bioscience’s dividend payout ratio (DPR) is currently 98.04%.
About Meridian Bioscience
Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.